Literature DB >> 23611705

Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.

Cyrille Boyer1, Joann Teo, Phoebe Phillips, Rafael B Erlich, Sharon Sagnella, George Sharbeen, Tanya Dwarte, Hien T T Duong, David Goldstein, Thomas P Davis, Maria Kavallaris, Joshua McCarroll.   

Abstract

Cancer is one of the most common causes of death worldwide. Two types of cancer that have high mortality rates are pancreatic and lung cancer. Despite improvements in treatment strategies, resistance to chemotherapy and the presence of metastases are common. Therefore, novel therapies which target and silence genes involved in regulating these processes are required. Short-interfering RNA (siRNA) holds great promise as a therapeutic to silence disease-causing genes. However, siRNA requires a delivery vehicle to enter the cell to allow it to silence its target gene. Herein, we report on the design and synthesis of cationic star polymers as novel delivery vehicles for siRNA to silence genes in pancreatic and lung cancer cells. Dimethylaminoethyl methacrylate (DMAEMA) was polymerized via reversible addition-fragmentation transfer polymerization (RAFT) and then chain extended in the presence of both cross-linkers N,N-bis(acryloyl)cistamine and DMAEMA, yielding biodegradable well-defined star polymers. The star polymers were characterized by transmission electron microscopy, dynamic light scattering, ζ potential, and gel permeation chromatography. Importantly, the star polymers were able to self-assemble with siRNA and form small uniform nanoparticle complexes. Moreover, the ratios of star polymer required to complex siRNA were nontoxic in both pancreatic and lung cancer cells. Treatment with star polymer-siRNA complexes resulted in uptake of siRNA into both cell lines and a significant decrease in target gene mRNA and protein levels. In addition, delivery of clinically relevant amounts of siRNA complexed to the star polymer were able to silence target gene expression by 50% in an in vivo tumor setting. Collectively, these results provide the first evidence of well-defined small cationic star polymers to deliver active siRNA to both pancreatic and lung cancer cells and may be a valuable tool to inhibit key genes involved in promoting chemotherapy drug resistance and metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611705     DOI: 10.1021/mp400049e

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  13 in total

Review 1.  siRNA delivery to the lung: what's new?

Authors:  Olivia M Merkel; Israel Rubinstein; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

2.  Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo.

Authors:  Christopher E Nelson; Arnold J Kim; Elizabeth J Adolph; Mukesh K Gupta; Fang Yu; Kyle M Hocking; Jeffrey M Davidson; Scott A Guelcher; Craig L Duvall
Journal:  Adv Mater       Date:  2013-12-16       Impact factor: 30.849

3.  Cationic branched polymers for cellular delivery of negatively charged cargo.

Authors:  Courtney A Follit; Shannon R Woodruff; Pia D Vogel; John G Wise; Nicolay V Tsarevsky
Journal:  J Drug Deliv Sci Technol       Date:  2017-04-07       Impact factor: 3.981

Review 4.  Polymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug delivery.

Authors:  Christine E Wang; Patrick S Stayton; Suzie H Pun; Anthony J Convertine
Journal:  J Control Release       Date:  2015-09-02       Impact factor: 9.776

Review 5.  Polymeric nanoparticles for targeted treatment in oncology: current insights.

Authors:  Rashmi H Prabhu; Vandana B Patravale; Medha D Joshi
Journal:  Int J Nanomedicine       Date:  2015-02-02

6.  Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.

Authors:  Joshua A McCarroll; Tanya Dwarte; Huricha Baigude; Jason Dang; Lu Yang; Rafael B Erlich; Kathleen Kimpton; Joann Teo; Sharon M Sagnella; Mia C Akerfeldt; Jie Liu; Phoebe A Phillips; Tariq M Rana; Maria Kavallaris
Journal:  Oncotarget       Date:  2015-05-20

7.  EBP50 regulates the apoptosis of pancreatic cancer cells by decreasing the expression levels of Bcl-2.

Authors:  Mengyao Ji; Lei Yuan; Xiaoguang Lv; Weiguo Dong; Xiulan Peng
Journal:  Exp Ther Med       Date:  2014-07-07       Impact factor: 2.447

8.  MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.

Authors:  George Sharbeen; Janet Youkhana; Amanda Mawson; Joshua McCarroll; Andrea Nunez; Andrew Biankin; Amber Johns; David Goldstein; Phoebe Phillips
Journal:  Oncotarget       Date:  2017-02-07

9.  Adenylyl cyclase‑associated protein 1‑targeted nanoparticles as a novel strategy for the treatment of metastatic non‑small cell lung cancer.

Authors:  Yang Liu; Shuanshuan Xie; Jie Zeng; Xiaolian Song; Min Tan; Dannong He; Jie Wang; Ping Wang; Jun Zhu; Changhui Wang
Journal:  Int J Oncol       Date:  2019-06-06       Impact factor: 5.650

10.  Thiol-Reactive Star Polymers Functionalized with Short Ethoxy-Containing Moieties Exhibit Enhanced Uptake in Acute Lymphoblastic Leukemia Cells.

Authors:  Thomas P Davis; Richard B Lock; Narges Bayat; Nathan McOrist; Nicholas Ariotti; May Lai; Keith Cs Sia; Yuhuan Li; James L Grace; John F Quinn; Michael R Whittaker; Maria Kavallaris
Journal:  Int J Nanomedicine       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.